DEXTROMETHORPHAN HYDROCHLORIDE

US Approved OTC

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25NO.ClH
Molecular Weight	307.858
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXTROMETHORPHAN HYDROCHLORIDE

Structure Search

SMILES

Cl.[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(OC)C=C34

InChI

InChIKey=SNDDIRAXSDUVKW-URVXVIKDSA-N

InChI=1S/C18H25NO.ClH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C18H25NO
Molecular Weight	271.3972
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2694543 http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099	Agonist 2662		205.0 nM [Ki]
Glutamate [NMDA] receptor subunit 3A 21 Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648	Antagonist 2760

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf	Primary		Approved 8360	MUCINEX DM Approved Use Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date 1.08319677E12
Pseudobulbar affect 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000221	Primary		Approved 8360	NUEDEXTA Approved Use NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date 1.28580479E12

C_max

Value	Dose	Co-administered	Analyte	Population
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: healthy age: adults sex: food status:

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	unhealthy, 19-52 years n = 16 Health Status: unhealthy Condition: chronic intractable partial onset seizures Age Group: 19-52 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	Sources: https://pubmed.ncbi.nlm.nih.gov/8741125
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	unhealthy, 19-67 years n = 11 Health Status: unhealthy Condition: Huntington's disease Age Group: 19-67 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	Sources: https://pubmed.ncbi.nlm.nih.gov/2529964
120 mg single, oral Recommended Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	healthy, 26.5 years n = 40 Health Status: healthy Age Group: 26.5 years Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	Sources: https://pubmed.ncbi.nlm.nih.gov/26294136
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	Other AEs: Ischemic colitis... Other AEs: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Ataxia (1 patient) Nystagmus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient	900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
Ataxia	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Lethargy	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Nystagmus	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579 inducer 768	inhibitor 1752	substrate 1193 inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2A6 704 CYP2B6 799 CYP2C8 901 CYP2C19 1463 CYP2E1 876	P-gp 1527	CYP1A2 689 CYP2B6 538

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2A6 736	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 985	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 985	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1909	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://www.eurekaselect.com/66423/article/lack-interaction-nmda-receptor-antagonists-dextromethorphan-and-dextrorphan-p	no
CYP2D6 1193	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4470	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4470
ZINC	ZINC000003201907	http://zinc15.docking.org/substances/ZINC000003201907

PubMed

Title	Date	PubMed
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.	1991 Mar-Apr	1685312
Visual hallucinations after combining fluoxetine and dextromethorphan.	1992 Oct	1530079
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.	2001	12001656
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.	2002 Aug 22	12151071
Consultation with the specialist: the central serotonin syndrome: paradigm for psychotherapeutic misadventure.	2002 Dec	12456895
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions.	2002 Dec	12433797
Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex.	2003 Feb 15	12576146
Total and corrected antioxidant capacity in hemodialyzed patients.	2003 Jul 1	12837136
mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.	2003 Mar	12637241
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".	2003 Nov	14586384
Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.	2003 Sep-Oct	12928596
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.	2004 Dec	15383492
Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents.	2004 Jul	15231978
Validated assays for human cytochrome P450 activities.	2004 Jun	15155557
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice.	2004 May 5	15084442
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.	2004 Nov	15286053
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study].	2005	17037292
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico.	2005	16416672
Epigenetic silencing of DSC3 is a common event in human breast cancer.	2005	16168112
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.	2005	16124035
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.	2005 Apr	15723099
Dextromethorphan psychosis, dependence and physical withdrawal.	2005 Dec	16318953
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.	2005 Jan	15626586
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity.	2005 Jul 19	15987631
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus.	2005 Jun	15930738
Side effects of dextromethorphan abuse, a case series.	2005 Sep	16122622
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.	2006 May	16634036
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.	2007	18096088
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.	2007 Apr	17225166
Effects of dextromethorphan on dopamine dependent behaviours in rats.	2007 Aug	17877148
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.	2007 Aug	17470523
Treatment of the common cold.	2007 Feb 15	17323712
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain.	2007 Jul	17573115
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.	2007 Jul	17565714
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method].	2007 Jun	17702393
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.	2007 Jun 1	17543114
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.	2007 Jun 1	17267297
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection.	2007 Nov 14	18000543
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.	2007 Spring	17461892
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems.	2008 Apr	18346904
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.	2008 Apr	18221780
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.	2008 Jan 8	18281903
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.	2008 Jul	18359183
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.	2008 Sep	18336967
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.	2009	19258215
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.	2009 Feb 18	19226451
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.	2009 Jan	19029129
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.	2009 Jan-Feb	19344034
[Bone anchored hearing aids (BAHA)].	2009 Mar	19343390

Patents

Sample Use Guides

In Vivo Use Guide

15-30 mg 3 to 4 times per day (cough) 20-30 mg twice daily (pseudobulbar affect)

Route of Administration: Oral

In Vitro Use Guide

In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:46:22 UTC 2023` Edited by `admin` on `Wed Jul 05 22:46:22 UTC 2023`
Record UNII	351KFH969D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXTROMETHORPHAN HYDROCHLORIDE

Common Name

English

DEXTROMETHORPHAN HCL

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HYDROCHLORIDE

Common Name

English

Dextromethorphan hydrochloride [WHO-DD]

Common Name

English

DEXTROMETHORPHAN HYDROCHLORIDE [VANDF]

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID70940040